Business Wire

FL-I-SQUARED-CAPITAL

Share
I Squared Capital Appoints Gautam Bhandari as Global Chief Investment Officer

I Squared Capital, a leading global infrastructure investment manager, today announced that Gautam Bhandari, co-founder and Managing Partner, has been appointed as I Squared Capital’s Global Chief Investment Officer, responsible for leading the firm’s global investment strategy in close collaboration with founder, Chairman and Managing Partner Sadek Wahba. This new appointment is part of additional changes to its management and governance structure that will build on the firm’s success to further institutionalize I Squared Capital for the coming decade and beyond.

In addition, I Squared Capital has named Mohamed Adel El-Gazzar and Harsh Agrawal as Senior Partners and members of the Executive Committee of the firm. The newly formed Executive Committee will lead the strategic development of the firm.

“These structural enhancements come at an important moment for I Squared,” said Dr. Wahba. “As we reflect on the tremendous success of the past decade, we are taking steps to further institutionalize our firm and ensure that we are well positioned to capitalize on the unique opportunities of the next decade and beyond.”

“As I Squared continues to grow, I look forward to working with the Executive Committee to ensure that new fundraises and investments are calibrated to the firm’s disciplined approach of investing in and building high-quality, world-class businesses for the future,” said Dr. Bhandari. “We believe the demand for infrastructure will continue to grow globally as many capital-intensive sectors of the economy, such as energy, telecommunications, and transportation urgently need to modernize and also address the ever-increasing demand for sustainable infrastructure.”

Dr. Bhandari, co-founder and Managing Partner, has been a member of the Investment Committees of I Squared Capital since inception and he chairs the boards of several I Squared Capital portfolio companies globally. Prior to I Squared Capital, he was a Managing Director at Morgan Stanley where, for over ten years, he worked on infrastructure investments, as well as banking and capital markets. He holds a Ph.D. in Chemistry from the University of Delaware, where he was the University Merit Fellow and recipient of the Joel L. Silver Award for the best doctoral dissertation work, and an MBA in Finance from the Stern School of Business at New York University, where he was an Amerada Hess Merit Scholar.

Furthermore, I Squared Capital has formed an Operating Committee to manage the operations of the firm and to support the continued global growth of the platform. The Operating Committee will consist of the firm’s Partners along with a broader group of senior executives of I Squared Capital. The global platform has grown to over 215 employees, having hired 81 professionals since the start of 2022.

In parallel, Adil Rahmathulla, Managing Partner, will be transitioning from his role at I Squared Capital over the coming year to pursue other opportunities. He will remain on the firm’s Investment Committees ahead of his eventual departure from the firm in June 2024.

Dr. Wahba and Dr. Bhandari stated, “We are extremely grateful to Adil for the vital role he has played in co-founding and growing I Squared Capital. He has been a great partner, and we are pleased he will continue to work closely with us over the coming year. We are confident he will be successful in his future endeavors, and we wish him all the best.”

“It has been a privilege to work alongside Sadek, Gautam and the I Squared Capital team to contribute to the firm’s growth into one of the world’s leading infrastructure investors,” said Mr. Rahmathulla. “I am immensely proud of what we have achieved over the last decade and am excited to watch and support the firm’s continued success. I am grateful to Sadek and Gautam for their partnership and friendship, and I look forward to continuing my journey as an investor and entrepreneur in the years ahead.”

As part of these changes, over twenty senior employees of the firm, in addition to the existing shareholders, will be investing their own capital into the equity ownership of I Squared Capital, further broadening the firm’s shareholder base and strengthening alignment of interests. No financial details will be disclosed.

About I Squared Capital

I Squared Capital is an independent global infrastructure manager with over $37 billion in assets under management focused on investing in North America, Europe, Asia, and Latin America. Headquartered in Miami, the firm has more than 215 professionals across its offices in Miami, Hong Kong, London, New Delhi, Singapore, Taipei, and Sydney. I Squared Capital has invested in a diverse portfolio of 77 companies in 59 countries with over 31,000 employees across the utilities, energy, digital infrastructure, transport, environmental infrastructure, and social infrastructure sectors providing essential services to millions of people around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005039/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon

Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release

The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered

TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release

TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents

AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release

Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce

ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release

Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye